Citadel Advisors
RGNX icon

Citadel Advisors’s Regenxbio RGNX Stock Holding History

Citadel Advisors’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46,641
Closed -$490K – 14032
2025
Q4 		$672K Sell
46,641
-8,882
-16% -$111K ﹤0.01% 8295
2025
Q3 		$536K Sell
55,523
-236,343
-81% -$2.09M ﹤0.01% 8960
2025
Q2 		$2.4M Sell
291,866
-735,670
-72% -$6.16M ﹤0.01% 5382
2025
Q1 		$7.35M Buy
1,027,536
+442,128
+76% +$3.29M ﹤0.01% 3301
2024
Q4 		$4.53M Buy
585,408
+382,177
+188% +$3.59M ﹤0.01% 4117
2024
Q3 		$2.13M Buy
203,231
+76,839
+61% +$937K ﹤0.01% 5417
2024
Q2 		$1.48M Buy
126,392
+17,895
+16% +$279K ﹤0.01% 5861
2024
Q1 		$2.29M Sell
108,497
-103,547
-49% -$1.84M ﹤0.01% 5264
2023
Q4 		$3.81M Sell
212,044
-509,117
-71% -$8.97M ﹤0.01% 4219
2023
Q3 		$11.9M Buy
721,161
+70,765
+11% +$1.28M ﹤0.01% 2467
2023
Q2 		$13M Sell
650,396
-92,961
-13% -$1.79M ﹤0.01% 2349
2023
Q1 		$14.1M Buy
743,357
+137,520
+23% +$3.04M ﹤0.01% 2352
2022
Q4 		$13.7M Buy
605,837
+563,266
+1,323% +$12.7M ﹤0.01% 2403
2022
Q3 		$1.13M Buy
+42,571
New +$1.26M ﹤0.01% 6735
2022
Q2 		– Sell
-156,673
Closed -$3.91M – 13909
2022
Q1 		$5.2M Sell
156,673
-389,044
-71% -$10.8M ﹤0.01% 4094
2021
Q4 		$17.8M Buy
545,717
+389,339
+249% +$13.3M ﹤0.01% 2165
2021
Q3 		$6.55M Buy
156,378
+35,313
+29% +$1.27M ﹤0.01% 3793
2021
Q2 		$4.7M Buy
121,065
+17,346
+17% +$620K ﹤0.01% 4578
2021
Q1 		$3.54M Sell
103,719
-109,459
-51% -$4.67M ﹤0.01% 5046
2020
Q4 		$9.67M Buy
213,178
+144,118
+209% +$5.04M ﹤0.01% 2673
2020
Q3 		$1.9M Buy
69,060
+14,115
+26% +$460K ﹤0.01% 4812
2020
Q2 		$2.02M Buy
54,945
+10,350
+23% +$386K ﹤0.01% 4557
2020
Q1 		$1.44M Sell
44,595
-4,876
-10% -$203K ﹤0.01% 4688
2019
Q4 		$2.03M Sell
49,471
-106,788
-68% -$4.22M ﹤0.01% 4399
2019
Q3 		$5.56M Buy
156,259
+122,409
+362% +$4.96M ﹤0.01% 2964
2019
Q2 		$1.74M Sell
33,850
-384,273
-92% -$19.2M ﹤0.01% 4757
2019
Q1 		$24M Sell
418,123
-21,536
-5% -$1.07M 0.01% 1187
2018
Q4 		$18.4M Sell
439,659
-52,141
-11% -$3.06M 0.01% 1296
2018
Q3 		$37.1M Buy
491,800
+456,151
+1,280% +$32.9M 0.02% 932
2018
Q2 		$2.56M Sell
35,649
-746,007
-95% -$35.6M ﹤0.01% 3719
2018
Q1 		$23.3M Sell
781,656
-206,096
-21% -$6M 0.01% 1009
2017
Q4 		$32.8M Buy
987,752
+378,612
+62% +$11.4M 0.02% 859
2017
Q3 		$20.1M Sell
609,140
-317,036
-34% -$7.14M 0.02% 1062
2017
Q2 		$18.3M Buy
926,176
+366,289
+65% +$7.09M 0.02% 1047
2017
Q1 		$10.8M Buy
559,887
+482,667
+625% +$9.31M 0.01% 1382
2016
Q4 		$1.43M Buy
77,220
+67,167
+668% +$1.28M ﹤0.01% 3360
2016
Q3 		$141K Buy
+10,053
New +$111K ﹤0.01% 6510
2015
Q4 		– Sell
-51,686
Closed -$1.14M – 9101
2015
Q3 		$1.14M Buy
+51,686
New +$1.32M ﹤0.01% 3640

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's RGNX Position: Q1 2026 in Review

Citadel Advisors sold out of Regenxbio (RGNX) in Q1 2026, closing a stake of 46,641 shares — an estimated $490K sold.

Citadel Advisors first reported a position in RGNX in Q3 2015 and held it in 38 quarters. The position peaked at $37.1M in Q3 2018. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • Citadel Advisors reported no remaining Regenxbio position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 46,641 Regenxbio shares in Q1 2026, an estimated $490K.
  • Citadel Advisors first reported a position in Regenxbio in Q3 2015 and held it in 38 quarters.
  • Citadel Advisors's Regenxbio position peaked at $37.1M in Q3 2018.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.